CTSK and osteoporosis: Rare disorders associated with impaired osteoclastic bone resorption may also have utility in treating osteoporosis, exemplified by pycnodysostosis caused by cathepsin K deficiency (14), for which the inhibitor Odanocatib was developed as a new anti-resorptive treatment for osteoporosis.